Baker 1995 a.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arm, flexible dose, double‐blind, single‐blind placebo run‐in BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 146 DSM‐III‐R PTSD, average age: 44 years (23‐73), 81% male, mean duration of diagnosis: 12.8 years, MDD not present, 60% combat‐related SCREENING Primary diagnosis: symptoms at least 6 months, CAPS >= 45, MADRS <= 22 Comorbidity: MADRS
Interventions	Description: brofaromine up to 150 mg/d vs placebo x 12 weeks
Outcomes	Primary outcomes: CAPS Secondary outcomes: IES, DTS, CGI NOTES: CGI (values not reported, CGI‐C obtained from Davidson et al, 1997), ITT (LOCF 1 post‐baseline assessment) values provided.
Notes	INDUSTRY SUPPORT Industry funded: Not mentioned Medication provided by industry: No Any of the authors work for industry: Yes ADDITIONAL INFORMATION Drop‐out rates: total of 35 Quality rating score: 15 Single‐blind placebo run‐in excluded 28 placebo‐responders Obtained additional HAM‐D and CAPS‐2 summary statistics from Sudie Back
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear